Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

1.

Phase II clinical study on the GEMOX regimen as second- line therapy for advanced ovarian cancer.

Yuan SF, Zhang LP, Zhu LJ, Chen WJ, Zheng WE, Xiong JP.

Asian Pac J Cancer Prev. 2013;14(6):3949-53.

PMID:
23886213
[PubMed - indexed for MEDLINE]
Free Article
2.

Outcome of single agent generic gemcitabine in platinum-resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma.

Suprasert P, Cheewakriangkrai C, Manopunya M.

Asian Pac J Cancer Prev. 2012;13(2):517-20.

PMID:
22524817
[PubMed - indexed for MEDLINE]
Free Article
3.

Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.

Bamias A, Bamia C, Zagouri F, Kostouros E, Kakoyianni K, Rodolakis A, Vlahos G, Haidopoulos D, Thomakos N, Antsaklis A, Dimopoulos MA.

Oncology. 2013;84(3):158-65. doi: 10.1159/000341366. Epub 2012 Dec 28.

PMID:
23296063
[PubMed - indexed for MEDLINE]
4.

Pegylated liposomal doxorubicin and gemcitabine in a fixed dose rate infusion for the treatment of patients with poor prognosis of recurrent ovarian cancer: a phase Ib study.

Crespo G, Sierra M, Losa R, Berros JP, Villanueva N, Fra J, Fonseca PJ, Luque M, Fernández Y, Blay P, Sanmamed M, Muriel C, Esteban E, Lacave AJ.

Int J Gynecol Cancer. 2011 Apr;21(3):478-85. doi: 10.1097/IGC.0b013e31820d738c.

PMID:
21436695
[PubMed - indexed for MEDLINE]
5.

Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand.

Pitakkarnkul S, Tangjitgamol S, Srijaipracharoen S, Manusirivithaya S, Pataradool K, Prutthiphongsit W, Khunnarong J, Thavaramara T.

Asian Pac J Cancer Prev. 2013;14(4):2421-7.

PMID:
23725151
[PubMed - indexed for MEDLINE]
Free Article
6.

Treatment of chemotherapy-induced anemia in ovarian cancer patients: does the use of erythropoiesis-stimulating agents worsen survival?

Rocconi RP, Sullivan P, Long B, Blaize M, Brown J, Arbuckle J, Bevis K, Estes JM, Reed E, Finan MA.

Int J Gynecol Cancer. 2012 Jun;22(5):786-91. doi: 10.1097/IGC.0b013e31825104f4.

PMID:
22552832
[PubMed - indexed for MEDLINE]
7.

BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study.

Lesnock JL, Darcy KM, Tian C, Deloia JA, Thrall MM, Zahn C, Armstrong DK, Birrer MJ, Krivak TC.

Br J Cancer. 2013 Apr 2;108(6):1231-7. doi: 10.1038/bjc.2013.70. Epub 2013 Mar 5.

PMID:
23462720
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

From randomized trial to practice: single institution experience using the GOG 172 i.p. chemotherapy regimen for ovarian cancer.

Aletti GD, Nordquist D, Hartmann L, Gallenberg M, Long HJ, Cliby WA.

Ann Oncol. 2010 Sep;21(9):1772-8. doi: 10.1093/annonc/mdq025. Epub 2010 Feb 5.

PMID:
20139154
[PubMed - indexed for MEDLINE]
Free Article
9.

Survivin expression as a prognostic factor in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadjuvant chemotherapy.

Gąsowska-Bodnar A, Bodnar L, Dąbek A, Cichowicz M, Jerzak M, Cierniak S, Kozłowski W, Baranowski W.

Int J Gynecol Cancer. 2014 May;24(4):687-96. doi: 10.1097/IGC.0000000000000108.

PMID:
24662134
[PubMed - indexed for MEDLINE]
10.

Gemcitabine for advanced endometrial cancer: a retrospective study of the Memorial sloan-Kettering Cancer Center experience.

Grisham RN, Adaniel C, Hyman DM, Ma W, Iasonos A, Aghajanian C, Konner J.

Int J Gynecol Cancer. 2012 Jun;22(5):807-11. doi: 10.1097/IGC.0b013e31824a33a2.

PMID:
22635030
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study.

Sabbatini P, Harter P, Scambia G, Sehouli J, Meier W, Wimberger P, Baumann KH, Kurzeder C, Schmalfeldt B, Cibula D, Bidzinski M, Casado A, Martoni A, Colombo N, Holloway RW, Selvaggi L, Li A, del Campo J, Cwiertka K, Pinter T, Vermorken JB, Pujade-Lauraine E, Scartoni S, Bertolotti M, Simonelli C, Capriati A, Maggi CA, Berek JS, Pfisterer J.

J Clin Oncol. 2013 Apr 20;31(12):1554-61. doi: 10.1200/JCO.2012.46.4057. Epub 2013 Mar 11.

PMID:
23478059
[PubMed - indexed for MEDLINE]
Free Article
12.

Prediction value of XRCC 1 gene polymorphism on the survival of ovarian cancer treated by adjuvant chemotherapy.

Miao J, Zhang X, Tang QL, Wang XY, Kai L.

Asian Pac J Cancer Prev. 2012;13(10):5007-10.

PMID:
23244100
[PubMed - indexed for MEDLINE]
Free Article
13.

Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).

Khemapech N, Oranratanaphan S, Termrungruanglert W, Lertkhachonsuk R, Vasurattana A.

Asian Pac J Cancer Prev. 2013;14(3):2131-5.

PMID:
23679331
[PubMed - indexed for MEDLINE]
Free Article
14.

Patterns of recurrence in patients treated with bevacizumab in the primary treatment of advanced epithelial ovarian cancer.

Rauh-Hain JA, Guseh SH, Esselen KM, Growdon WB, Schorge JO, Horowitz NS, Krasner CN, del Carmen MG, Birrer MJ, Dizon DS.

Int J Gynecol Cancer. 2013 Sep;23(7):1219-25. doi: 10.1097/IGC.0b013e31829f17c9.

PMID:
23975042
[PubMed - indexed for MEDLINE]
15.

Prognostic factors and clinical outcome of patients with recurrent early-stage epithelial ovarian cancer: an Italian multicenter retrospective study.

Gadducci A, Cosio S, Zola P, Sostegni B, Fuso L, Sartori E.

Int J Gynecol Cancer. 2013 Mar;23(3):461-8. doi: 10.1097/IGC.0b013e318286665b.

PMID:
23370604
[PubMed - indexed for MEDLINE]
16.

Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.

Chang SJ, Bristow RE, Ryu HS.

Ann Surg Oncol. 2012 Dec;19(13):4059-67. doi: 10.1245/s10434-012-2446-8. Epub 2012 Jul 6.

PMID:
22766983
[PubMed - indexed for MEDLINE]
17.

Adjuvant platinum-based chemotherapy in patients with epithelial ovarian cancer: prognostic factors and final outcome.

Grivas A, Lianos E, Internos I, Papaxoinis G, Tselepatiotis E, Ziras N, Athanasiou AE.

J BUON. 2010 Oct-Dec;15(4):647-51.

PMID:
21229624
[PubMed - indexed for MEDLINE]
18.

The use of Fluorouracil (5-FU) and leucovorin in women with heavily pretreated advanced ovarian carcinoma.

Peled Y, Levavi H, Krissi H, Weill Y, Sabah G, Eitan R.

Am J Clin Oncol. 2013 Oct;36(5):472-4. doi: 10.1097/COC.0b013e3182549399.

PMID:
22706176
[PubMed - indexed for MEDLINE]
19.

Quality of life in ovarian cancer patients choosing to receive salvage chemotherapy or palliative treatment.

Srisuttayasathien M, Khemapech N.

Asian Pac J Cancer Prev. 2013;14(12):7669-74.

PMID:
24460351
[PubMed - indexed for MEDLINE]
Free Article
20.

Feasibility of trials in ovarian cancer by line of therapy and platinum sensitivity.

Shaboodien R, Diamantis N, Blagden S, Gabra H, Agarwal R.

Int J Gynecol Cancer. 2013 Mar;23(3):481-7. doi: 10.1097/IGC.0b013e31828702f6.

PMID:
23392404
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk